$329.97
1.38% today
Nasdaq, Apr 03, 06:47 pm CET
ISIN
US5588681057
Symbol
MDGL
Sector
Industry

Madrigal Pharmaceuticals, Inc. Stock price

$334.60
+21.13 6.74% 1M
+125.45 59.98% 6M
+26.03 8.44% YTD
+90.10 36.85% 1Y
+236.77 242.02% 3Y
+274.01 452.24% 5Y
+265.30 382.83% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+10.62 3.28%
ISIN
US5588681057
Symbol
MDGL
Sector
Industry

Key metrics

Market capitalization $7.39b
Enterprise Value $6.58b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 36.51
P/S ratio (TTM) P/S ratio 41.02
P/B ratio (TTM) P/B ratio 9.76
Revenue (TTM) Revenue $180.13m
EBIT (operating result TTM) EBIT $-497.88m
Free Cash Flow (TTM) Free Cash Flow $-457.03m
Cash position $931.25m
EPS (TTM) EPS $-22.11
P/E forward negative
P/S forward 12.80
EV/Sales forward 11.39
Short interest 26.47%
Show more

Is Madrigal Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Madrigal Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:

15x Buy
88%
1x Hold
6%
1x Sell
6%

Analyst Opinions

17 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:

Buy
88%
Hold
6%
Sell
6%

Financial data from Madrigal Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
180 180
-
100%
- Direct Costs 7.33 7.33
1,283% 1,283%
4%
173 173
32,704% 32,704%
96%
- Selling and Administrative Expenses 434 434
303% 303%
241%
- Research and Development Expense 236 236
13% 13%
131%
-497 -497
31% 31%
-276%
- Depreciation and Amortization 1.10 1.10
108% 108%
1%
EBIT (Operating Income) EBIT -498 -498
31% 31%
-276%
Net Profit -466 -466
25% 25%
-259%

In millions USD.

Don't miss a Thing! We will send you all news about Madrigal Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Madrigal Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
23 days ago
Fred Craves, Ph.D. to retire from Madrigal's Board of Directors in July 2025 CONSHOHOCKEN, Pa.
Positive
Seeking Alpha
about one month ago
Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges. Madrigal's Phase 3 trial aims to expand Rezdiffra's label to early cirrhosis by 2027, with EMA approval expected in mid-2025. GLP-1s like semaglutide and tirzepatide show promising MASH results, potentially di...
Positive
Seeking Alpha
about one month ago
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales up 66% to $103.3m. Despite a net loss of $466m in 2024, Madrigal's cash position improved to $931m, and Rezdiffra's market potential remains significant with no current competitors. Positive study data and upcoming European approval could further boost Rezdiffra's market p...
More Madrigal Pharmaceuticals, Inc. News

Company Profile

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Head office United States
CEO William Sibold
Employees 528
Founded 2011
Website www.madrigalpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today